Business context and reporting period
Filing/entity mismatch: The supplied filing is Avista Healthcare Public Acquisition Corp.’s Form 10-K for the year ended December 31, 2016, not an Organogenesis Holdings Inc. filing. It reports a newly formed blank-check company (SPAC), not an operating healthcare business. It had no operations or revenue and was seeking a business combination, with a stated focus on healthcare.
The filing includes unaudited fourth-quarter results. The public offering closed October 14, 2016; the company had until October 14, 2018 to complete a business combination.
Financial results and position
- Revenue and margins: No operating revenue; margins are not meaningful. Management said revenue would not begin before a business combination.
- Loss: FY 2016 net loss was $208,698, versus $25,162 from inception through December 31, 2015. Q4 2016 net loss was $178,156; basic and diluted loss per share was $0.02 for the quarter and $0.03 for FY 2016.
- Cash flow: Operating cash use was $562,233 in FY 2016. Financing activities provided $311.5 million, principally from the public offering and private placement; $310 million was placed in the trust account.
- Assets and liquidity: At year-end, total assets were $311.4 million, including $310 million in the trust account and $1.04 million in cash. Management separately reported $561,708 available outside the trust for working capital. Working capital was $957,551.
- Liabilities and equity: Total liabilities were $11.3 million, including $10.85 million of deferred underwriting commissions payable if a business combination closes. Shareholders’ equity was $5,000,001; $295.1 million of Class A shares were classified as subject to possible redemption.
- Debt: No long-term debt was reported at year-end. A $300,000 sponsor note had been repaid at the offering close. The company could seek sponsor working-capital loans, but none was reported outstanding at year-end.
Changes, outlook, and risks
Compared with the 2015 inception period, the 2016 loss increased as the company completed its offering and incurred operating and formation costs. The $310 million trust balance arose from the offering and related private placement; it was held in cash at year-end and invested in short-term U.S. Treasury bills on January 6, 2017. Management stated it expected to have enough working capital for the search process and to complete a combination by the deadline, but noted that additional financing might be needed for a transaction or if costs exceeded estimates. No target, definitive agreement, or specific transaction outlook was disclosed.
Key risks include failing to complete a combination within 24 months (public shares would then be redeemed, while warrants would expire worthless), shareholder redemptions reducing transaction cash, claims against the trust, limited working capital outside the trust, potential dilution from founder shares and warrants, conflicts of interest involving the sponsor and its affiliates, and uncertainty over access to additional financing. Sponsor indemnification for certain trust shortfalls may be difficult to collect. No material legal proceedings were reported. The auditor issued an unqualified opinion; management concluded disclosure controls were effective, while the filing did not include an internal-control effectiveness assessment or auditor attestation.
Investor facts to verify
- Confirm the filing is for Avista Healthcare Public Acquisition Corp., not Organogenesis Holdings Inc., before using it for company analysis.
- Reconcile the reported $1.04 million cash balance with the $561,708 cited as working capital available outside the trust.
- Verify the status and permitted uses of the $310 million trust balance, the deferred $10.85 million underwriting commission, and the October 14, 2018 combination deadline.
- Review redemption provisions, sponsor indemnity limitations, founder-share conversion terms, and warrant exercise and dilution terms.
- Check subsequent filings for a target announcement, financing, changes in trust investments, or developments affecting the stated deadline.